Literature DB >> 31302481

Low-dose tetracycline exposure alters gut bacterial metabolism and host-immune response: "Personalized" effect?

Tharushi P Keerthisinghe1, Mengjing Wang2, Yingdan Zhang2, Wu Dong3, Mingliang Fang4.   

Abstract

The human gut microbiome (GM) in healthy people is chronically exposed to tetracycline (TET) via environmental exposure and dietary uptake. However, limited information is available on its effect on the GM metabolome and effect on the host, especially at the dietary exposure level. Here, we investigated how TET at both sub-pharmaceutical and dietary exposure levels affects the metabolome and the secretome-induced host immune response by studying several representative gut bacteria. Interestingly, the metabolome showed a highly species-specific pattern with a distinct dose-response relationship. B. fragilis was highly sensitive to TET and vitamin, nucleotide, and amino acid metabolism pathways were the most vulnerable metabolic pathways at dietary exposure level. For key metabolite short chain fatty acids, TET significantly induced the synthesis of butyrate in B. fragilis, rather than C. sporogenes and E. coli. Furthermore, TET induced the release of lipopolysaccharides (LPS) in E. coli and enhanced the immune response; however, there was no obvious effect on B. fragilis. Interestingly, the overall immune response modulation with TET exposure relied on the ratio between E. coli and B. fragilis, possibly due to the neutralization of active LPS from E. coli by the LPS from B. fragilis. Overall, our results showed that the effect of TET from environmental exposure on the host health would be highly dependent on the GM composition, especially for the gut bacterial metabolome and secretome induced immune response.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Gut bacteria; Immune response; Metabolism; Tetracycline

Mesh:

Substances:

Year:  2019        PMID: 31302481     DOI: 10.1016/j.envint.2019.104989

Source DB:  PubMed          Journal:  Environ Int        ISSN: 0160-4120            Impact factor:   9.621


  6 in total

Review 1.  Tetracycline use in treating osteoarthritis: a systematic review.

Authors:  Brooks N Platt; Cale A Jacobs; Caitlin E W Conley; Austin V Stone
Journal:  Inflamm Res       Date:  2021-01-29       Impact factor: 4.575

Review 2.  Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.

Authors:  Iva Markulin; Marija Matasin; Viktorija Erdeljic Turk; Melita Salković-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2022-01-04       Impact factor: 3.850

3.  Association between new onset type 1 diabetes and real-world antibiotics and neonicotinoids' exposure-related gut microbiota perturbation.

Authors:  Zhen-Ran Xu; Xiao-Xiao Yuan; Rui-Min Chen; Hai-Yan Wei; Lin-Qi Chen; Hong-Wei Du; Gui-Mei Li; Yu Yang; Xiao-Juan Chen; Xin Fang; Fei-Hong Luo
Journal:  World J Pediatr       Date:  2022-07-29       Impact factor: 9.186

4.  Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity.

Authors:  Theresa L Montgomery; Axel Künstner; Josephine J Kennedy; Qian Fang; Lori Asarian; Rachel Culp-Hill; Angelo D'Alessandro; Cory Teuscher; Hauke Busch; Dimitry N Krementsov
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-19       Impact factor: 11.205

5.  Prediction of Minocycline Activity in the Gut From a Pig Preclinical Model Using a Pharmacokinetic -Pharmacodynamic Approach.

Authors:  Quentin Vallé; Béatrice B Roques; Alain Bousquet-Mélou; David Dahlhaus; Felipe Ramon-Portugal; Véronique Dupouy; Delphine Bibbal; Aude A Ferran
Journal:  Front Microbiol       Date:  2021-07-09       Impact factor: 5.640

6.  Acute and long-term effects of antibiotics commonly used in laboratory animal medicine on the fecal microbiota.

Authors:  Scott W Korte; Rebecca A Dorfmeyer; Craig L Franklin; Aaron C Ericsson
Journal:  Vet Res       Date:  2020-09-14       Impact factor: 3.683

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.